Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial

Clinical Breast Cancer

Volumn 3, Issue SUPPL. 2, 2002, Pages

  Heys, Steven D ^a   Hutcheon, Andrew W ^a   Sarkar, Tarun K ^a   Ogston, Keith N ^a   Miller, Iain D ^a   Payne, Simon ^a   Smith, Ian ^a   Walker, Leslie G ^b   Eremin, Oleg ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

Cyclophosphamide; Doxorubicin; Pathological response; Prednisone; Sequential therapy; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ONDANSETRON; PREDNISONE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 0036814394     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.s.015     Document Type: Article

References (24)

1. De Lena M, Zucali R, Viganotti G, et al. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978; 1:53-59.
2. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990; 66:119-129.
3. Hortobagyi G, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62:2507-2516.
4. Heys SD, Sarkar TK, Ah-See AK, et al. Multimodality treatment in the management of locally advanced breast cancer. JR Coll Surg Edinb 1993; 38:9-15.
5. Heys SD, Eremin JM, Sarkar TK, et al. Role of multimodality therapy in the management of locally advanced carcinoma of the breast. J Am Coll Surg 1994; 179:493-504.
6. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimetres or more. J Natl Cancer Inst 1990; 82:1539-1545.
7. Bonnadonna G, Valagusswa P, Zucali R, et al. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 1996; 45:227-243.
8. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352:930-942.
9. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224-423.
10. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10:47-52.
11. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 30A:645-652.
12. Semiglazov VF, Topuzov EE, Bavli JL, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994; 5:591-595.
13. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13:547-552.
14. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30:96-102.
15. Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998; 9:1179-1184.
16. Nabholtz J-M, Tonkin K, Smylie M, et al. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expert Opin Pharmacother 2000; 1:187-206.
17. Doliny P, Hurley J, Raez L, et al. Phase II trial of neoadjuvant (NEO) docetaxel and cisplatin (DP) for the treatment of locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 1999; 18:84a (Abstract #319).
18. Dorr V, Ford L, Reynolds M, et al. A pilot multimodality study with preoperative and post-operative chemotherapy with taxotere (docetaxel) and adriamycin (doxorubicin) (TA) for locally advanced breast cancer. Proc Am Soc Clin Oncol 1999; 18:92a (Abstract #346).
19. Laurence V, Extra JM, Girre V, et al. Phase II study of sequential docetaxel (Taxotere, TXT) and doxorubicin (DOX) as primary chemotherapy (CT) for large operable breast cancer (BC). Proc Am Soc Clin Oncol 1999; 8:98a (Abstract #367).
20. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456-1466.
21. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
22. Smith IC, Miller ID. Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs 2001; 12(suppl 1):S25-S29.
23. Chetty U, Jack W, Prescott RJ, et al. Management of the axilla in operable breast cancer treated by breast conservation: a randomised clinical trial. Br J Surg 2000; 87:163-169.
24. Eltahir A, Heys SD, Hutcheon AW, et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 1998; 75:127-132.